Current Clinical Trials in Pemphigus and Pemphigoid

Area of Science:

• Dermatology
• Immunology
• Translational Research

Background:

• Autoimmune bullous dermatoses (AIBDs) are rare, chronic inflammatory skin conditions causing blisters and erosions due to autoantibodies targeting skin adhesion molecules.
• Classified as pemphigus (intraepidermal) or pemphigoid (subepidermal) based on blister location, AIBDs were historically life-threatening before immunosuppressive therapies.
• While systemic steroids and immunosuppressants control disease, long-term use carries significant adverse events.

Purpose of the Study:

• To review current clinical trials for pemphigus and pemphigoid.
• To discuss the underlying rationale for these AIBD clinical trials.
• To foster insights into AIBD translational research for improved patient outcomes.

Main Methods:

• Review of current clinical trials for AIBDs, specifically pemphigus and pemphigoid.
• Discussion of the scientific rationale driving these therapeutic investigations.
• Analysis of emerging treatment targets based on AIBD pathogenesis.

Main Results:

• Novel therapeutic targets for AIBDs are emerging based on a deeper understanding of disease pathogenesis.
• Several novel treatments are currently under evaluation in ongoing clinical trials.
• The review highlights the translational research landscape for AIBDs.

Conclusions:

• Despite advancements, effective and safer treatments for AIBDs are still needed.
• Current clinical trials explore novel targets to overcome limitations of existing immunosuppressive therapies.
• Translational research is crucial for advancing AIBD patient care and developing targeted therapies.